Bayesian inference for a principal stratum estimand on recurrent events truncated by death

Biometrics. 2023 Dec;79(4):3792-3802. doi: 10.1111/biom.13831. Epub 2023 Jan 30.

Abstract

Recurrent events are often important endpoints in randomized clinical trials. For example, the number of recurrent disease-related hospitalizations may be considered as a clinically meaningful endpoint in cardiovascular studies. In some settings, the recurrent event process may be terminated by an event such as death, which makes it more challenging to define and estimate a causal treatment effect on recurrent event endpoints. In this paper, we focus on the principal stratum estimand, where the treatment effect of interest on recurrent events is defined among subjects who would be alive regardless of the assigned treatment. For the estimation of the principal stratum effect in randomized clinical trials, we propose a Bayesian approach based on a joint model of the recurrent event and death processes with a frailty term accounting for within-subject correlation. We also present Bayesian posterior predictive check procedures for assessing the model fit. The proposed approaches are demonstrated in the randomized Phase III chronic heart failure trial PARAGON-HF (NCT01920711).

Keywords: Bayesian analysis; causal inference; principal stratum; recurrent events.

MeSH terms

  • Bayes Theorem
  • Chronic Disease
  • Heart Failure* / drug therapy
  • Humans

Associated data

  • ClinicalTrials.gov/NCT01920711